Table 2.
MRD (3 months) | Status (preTCTH) | Status (end of study) |
Immunoglobulin type | |
---|---|---|---|---|
1 | − | VGPR | D | IgG |
2 | − | CR | CR | IgG |
3 | − | CR | CR | IgG |
4 | − | VGPR | D | IgG |
5 | − | CR | CR | Kappa light chain |
6 | − | PR | D | IgA |
7 | + | PR | VGPR | IgG |
8 | − | PR | VGPR | IgA |
9 | − | CR | CR | Kappa light chain |
10 | − | VGPR | R | Lambda light chain |
11 | + | PR | D | IgG |
12 | − | CR | VGPR | IgG |
13 | − | CR | CR | IgG |
14 | − | VGPR | PR | IgG |
15 | + | PR | D | IgA |
16 | + | PR | R | IgA |
17 | − | CR | ∗ | IgG |
18 | + | VGPR | CR | IgG |
19 | + | CR | VGPR | IgG |
20 | + | CR | CR | IgG |
21 | + | CR | CR | Lambda light chain |
22 | + | VGPR | VGPR | IgG |
23 | + | PR | VGPR | IgG |
25 | − | VGPR | VGPR | Kappa light chain |
28 | − | PR | D | IgG |
30 | − | VGPR | CR | IgG |
31 | − | CR | CR | IgG |
32 | − | VGPR | VGPR | IgG |
33 | − | CR | VGPR | IgG |
35 | + | PR | R | IgA |
36 | − | PR | VGPR | Kappa light chain |
37 | − | PR | D | IgA |
38 | + | VGPR | VGPR | IgG |
39 | + | VGPR | VGPR | Kappa light chain |
40 | + | VGPR | VGPR | IgA |
41 | + | PR | D | IgA |
42 | + | PR | PR | IgA |
43 | − | VGPR | VGPR | IgG |
44 | − | VGPR | VGPR | IgA |
45 | − | VGPR | VGPR | IgG |
(D) Died; (R) relapse; (PR) partial remission; (VGPR) very good PR; (CR) complete remission.
(+) FCM > 0,01% neoplastic PC immunophenotype.
(−) FCM ≤ 0,01% PC neoplastic immunophenotype.